20 articles
A Phase IIa trial explores whether the HIF-PHI drug daprodustat can safely replace EPO injections in hemodialysis patients with anemia.
UCSF study reveals how metformin and trimethoprim interfere with thiamine uptake, potentially affecting energy metabolism.
Phase 4 trial tests whether alirocumab can better control non-HDL cholesterol in high-risk type 2 diabetics failing statin therapy.
275-patient study tests novel liver-targeted therapy for NASH, a serious form of fatty liver disease affecting millions worldwide.
A completed trial investigates whether replenishing glutathione precursors can reverse metabolic dysfunction in elderly adults.
A completed Maastricht trial tests whether targeted protein and exercise can boost muscle protein synthesis before dialysis becomes necessary.
Enanta Pharmaceuticals tests its FXR agonist EDP-305 in a completed Phase 2 randomized trial for non-alcoholic steatohepatitis.
Eli Lilly's phase 3 trial pits a novel weekly basal insulin against the gold-standard daily insulin degludec in type 1 diabetes patients.
A completed Danish trial investigates how blocking IL-6 signaling with tocilizumab alters fat, glucose, and protein metabolism in humans.
176-person trial tested whether pioglitazone could improve liver health by targeting insulin resistance in patients with fatty liver disease.
Carmot Therapeutics tests CT-868, a novel dual incretin receptor agonist, for HbA1c reduction in overweight and obese adults with poorly controlled T2DM.
Takeda's Phase 1 trial evaluates the safety and tolerability of TAK-510, a novel injectable agent targeting nausea and vomiting, across escalating doses.
University of Pennsylvania researchers investigated how insulin resistance and testosterone interact in women after menopause.
Major trial of 10,251 diabetics reveals surprising outcomes from aggressive blood sugar, blood pressure, and cholesterol management.
Stanford study tests whether GLP-1 drug exenatide can restore insulin function and promote weight loss in people with prediabetes.
Clinical trial tested whether metformin could improve surgical outcomes and reduce hospital stays in non-diabetic older patients.
Columbia University tested whether the diabetes drug metformin could slow memory loss in people with mild cognitive impairment.
Researchers mapped how anesthetics, nitric oxide, and other drugs alter hemoglobin's grip on oxygen — with real implications for critical care.
A Danish case-control trial uses gold-standard metabolic testing to uncover how mtDNA mutations impair muscle glucose uptake and drive insulin resistance.
Clinical trial tested whether metformin could enhance resistance training benefits for muscle mass and strength in older adults.
